SEC Form 4 · accession 0001127602-15-004379
ALLERGAN INC · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deborah Dunsire
Director
Period of report
Feb 2, 2015
Accepted (ET)
Feb 4, 2015 · 6:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000850693
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Phantom Stock UnitsF2,F1,F3 | — | Feb 2, 2015 | A | 14 | A | — | — | Common Stock | 14 | 8,842 | D |
| Phantom Stock UnitsF2,F1,F3 | — | Feb 3, 2015 | A | 11 | A | — | — | Common Stock | 11 | 8,853 | D |
Explanation of responses
- F1Converts to common stock on a 1-for-1 basis.
- F2Phantom stock units acquired under the Allergan, Inc. Deferred Directors' Fee Program.
- F3Phantom stock units are to be settled 100% in common stock upon the Reporting Person's retirement as an Allergan, Inc. director.